

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Bloomage BioTechnology Corporation Limited

華熙生物科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 00963)

VOLUNTARY ANNOUNCEMENT

SHAREHOLDING STRUCTURE OF THE COMPANY

AS AT 24 JUNE 2016

This is a voluntary announcement of Bloomage BioTechnology Corporation Limited (the “**Company**” together with its subsidiaries, the “**Group**”) to update the shareholders of the Company (the “**Shareholders**”) and potential investors on the shareholding structure of the Company as at 24 June 2016.

Reference is made to the announcement (“**2010 Announcement**”) made by the Securities and Futures Commission (“**SFC**”) on 8 February 2010 regarding the then high concentration of shareholding in the Company. In this respect, the board (“**Board**”) of directors of the Company (the “**Directors**”) wishes to inform the Shareholders and potential investors that the SFC stated on its website and in the 2010 Announcement that the 2010 Announcement only reflected the status of the Company’s shareholding structure as at the date referred to in the 2010 Announcement, i.e. 25 January 2010. Therefore, Shareholders and potential investors should note that the information disclosed in the 2010 Announcement might not be applicable to the Company as of a subsequent date or accurately reflect the status of the Company’s most up-to-date shareholding structure. The Company wishes to remind Shareholders and potential investors to exercise caution when interpreting or relying on such information contained in the 2010 Announcement.

The Company wishes to inform the Shareholders and potential investors that the shareholding structure of the Company as at 24 June 2016, has been diversified instead of highly concentrated as compared with the shareholding structure of the Company as at 25 January 2010. Since the 2010 Announcement, the Company has made a concerted effort to broaden its shareholders base. Details of which are as follows:

On 19 September 2012, the Company entered into a warrant subscription agreement with Perfect Good Investment Limited, an independent third party not connected with the Company or its connected person (“**Independent Third party**”) and issued 20,000,000 warrants on 8 October 2012. Following the exercise of the rights attached to the warrants, the Company allotted and issued an aggregate of 20,000,000 shares of the Company (the “**Shares**”) on 2013, representing approximately 6.41% of the issued share capital of the Company as at the date of the agreement.

On 5 November 2015, the Company and Ora Investment Pte. Ltd. (“**ORA**”) (an investment vehicle managed by GIC Pte. Ltd’s (“**GIC**”) private equity and infrastructure group, GIC is an independent sovereign wealth fund established to manage Singapore’s foreign reserves) entered into a shares and convertible bonds subscription agreement. Pursuant to the shares and convertible bonds subscription agreement and upon completion of the subscription on 20 November 2015, the Company allotted and issued a total of 16,145,834 Shares to ORA, representing approximately 4.84% of the issued share capital of the Company as at the date of the agreement. Both ORA and GIC are Independent Third Parties.

In addition, the Company had on 8 January 2016 allotted and issued a total of 9,687,500 Shares to an aggregate of 23 employees and senior management pursuant to the respective management subscription agreements entered into between the Company and each of the employees and/or senior management on 6 November 2015, representing approximately 2.90% of the issued share capital of the Company as at the date of the agreements.

To allow the Shareholders and potential investors to have a better understanding of the Company's recent shareholding structure, to the best of the knowledge of the Board having made all reasonable enquiries and based on the information available, the Board has analysed the shareholding structure of the Company as at 24 June 2016, which is as follows:

	Number of Shares held <small>(Note 1)</small> <i>(Shares)</i>	% of total number of issued Shares <i>(%)</i>
Zhao Yan <i>(Note 2)</i>	183,720,000	50.77
GIC <i>(Note 3)</i>	16,145,834	4.46
Directors (excluding Zhao Yan) <i>(Note 4)</i>	6,866,876	1.90
A group of 58 institutional Shareholders which held 100,000 Shares or more (excluding GIC)	106,534,082	29.44
A group of 39 private Shareholders who held 100,000 Shares or more (excluding the Directors)	21,420,000	5.92
Other Shareholders	<u>27,170,542</u>	<u>7.51</u>
	<u><u>361,857,334</u></u>	<u><u>100</u></u>

Note 1: Based on the ownership of interests investigation done by the Company according to the Division 5 Part XV of the Securities and Futures Ordinance.

Note 2: Ms. Zhao Yan is the Chairman and an executive Director. Out of the Shares held by Ms. Zhao Yan, 182,520,000 Shares are held by AIM First Investments Limited (“AFI”), which is a company wholly-owned by Ms. Zhao Yan. Therefore, Ms. Zhao is deemed, or taken to be, interested in all the Shares and underlying Shares which are beneficially owned by AFI for the purpose of the Securities and Futures Ordinance.

Note 3: These are the Shares issued to ORA. Details of the subscription by ORA are set out in the Company's announcements dated 5 November 2015 and 20 November 2015.

Note 4: The Directors include Mr. Jin Xuekun, Mr. Gong Anmin and Ms. Wang Aihua (all of them are executive Directors) and Mr. Yau Wai Yan (the non-executive Director).

The above demonstrates that the shareholding structure of the Company as at 24 June 2016 has been diversified as compared with that as at 25 January 2010.

To further demonstrate the diversity of the shareholding structure of the Company and that the 2010 Announcement is no longer applicable to the Company as at the date of this announcement, the Shareholders and potential investors may refer to the information available to the public from the CCASS Shareholding Search published on the website of HKEX News. According to the website of HKEX News, as of 31 August 2016, there were 120 CCASS participants holding approximately 97.34% Shares.

The high concentration of shareholding in the Company as at 25 January 2010 as stated in the 2010 Announcement is no longer valid and should not be used as a basis to evaluate the current status of the shareholding structure of the Company. The Shareholders and potential investors should exercise caution in interpreting or relying on any information regarding the Group published in the press which has not been confirmed by the Company.

By order of the Board
Bloomage BioTechnology Corporation Limited
Zhao Yan
Chairman

Hong Kong, 5 September 2016

As at the date of this announcement, the executive directors are Ms. Zhao Yan, Mr. Jin Xuekun, Mr. Gong Anmin and Ms. Wang Aihua; the non-executive director is Mr. Yau Wai Yan; the independent non-executive directors are Ms. Zhan Lili, Mr. Li Junhong and Mr. Xue Zhaofeng.